Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AZ, BMS to Jointly Commercialize Dapagliflozin in Japan
December 22, 2008
- 7 Organizations Call For Further Discussions on Online Sales of Drugs
December 22, 2008
- Sales of Cytotoxic Chemotherapeutics to Peak at US$16.5 Bil. in 2013
December 22, 2008
- Regulatory Reform Council to Not Include Online Sales of Drugs in Its Recommendation
December 22, 2008
- BUSINESS NEWS IN BRIEF
December 22, 2008
- Crestor Reduces CV Risk in Patients with High High-Sensitive CRP Levels: JUPITER Study
December 22, 2008
- New Fees Related to Generics Claimed by Only a Few Pharmacies
December 22, 2008
- Control of Postprandial Hyperglycemia Important to Prevent CV Events: Prof. Tajima
December 22, 2008
- Most Women Have Not Been Examined for Breast Cancer Despite Willingness
December 22, 2008
- High % of ED Patients with Underlying Conditions Satisfied with Levitra: Bayer Schering
December 22, 2008
- Nichi-Iko Merges 3 Subsidiaries
December 22, 2008
- GLP-1 Analogues, DPP-4 Inhibitors to Cut Treatment Cost for Diabetes: Dr Kobayashi
December 22, 2008
- Daiichi Sankyo Applies for Olmesartan + Ca Blocker Combination
December 22, 2008
- Relenza Should Be More Effectively Used in Combination with Tamiflu: Prof. Matsumoto
December 22, 2008
- DB of Medical Bills to Help Drug Risk Assessment
December 22, 2008
- Prescription of Tamiflu by Phone to Be Permitted upon Onset of Pandemic of New-Type Flu
December 22, 2008
- Research on Biomarkers Essential to Develop Anticancer Drugs: Dr Inoue
December 15, 2008
- Pfizer to Break Dependence on Blockbusters: Mr Iwasaki
December 15, 2008
- Tripartite Collaboration Needed to Bring Benefits of iPS Cells to Patients: Prof. Yamanaka
December 15, 2008
- Points to Remember in Developing Drugs for OAB Outlined by Former PMDA Reviewer
December 15, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…